首页> Expert review of gastroenterology & hepatology> High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study.

High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Samar K,Darweesh

第一单位： Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University , Cairo , Egypt.

作者： Samar K,Darweesh ^[1] ; Kadry,Elsaeed ^[2] ; Heba,Omar ^[1] ; Maissa,El Raziky ^[1] ; Wafaa,Elakel ^[1] ; Magdy,Elserafy ^[1] ; Sohier Ahmed,Ismail ^[3] ; Ahmed A,Gomaa ^[4] ; Mai,Mehrez ^[5] ; Mahamed,El Kassas ^[6] ; Mohamed,Abdullah ^[7] ; Mohammed Kamal,Shaker ^[8] ; Gamal,Esmat ^[1] ; Yehia,El Shazly ^[2] ; Wahid,Doss ^[1] ; Imam,Waked ^[9]

作者单位： Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University , Cairo , Egypt. ^[1] General Medicine, Hepatology and Gastroenterology Department, Faculty of Medicine, Ain Shams University , Cairo , Egypt. ^[2] NHTMRI , Cairo , Egypt. ^[3] Tropical Medicine Department, El- Fayoum University , Cairo , Egypt. ^[4] Hepatology-Internal Medicine Department, National Hepatology, and Tropical Medicine Research Institute , Cairo , Egypt. ^[5] Endemic Medicine Department, Faculty of Medicine, Helwan University , Cairo , Egypt. ^[6] Medical Research Division, National Research Center , Cairo , Egypt. ^[7] Tropical Medicine Department, Ain Shams University , Cairo , Egypt. ^[8] Hepatology Department, National Liver Institute, Menoufiya University , Shebeen EL Kom , Egypt. ^[9]

关键词 Chronic HCV Genotype 4 Direct acting antivirals failure daclatasvir interval ribavirin safety sofosbuvir virologic response